Vita Life Sciences Expects Fiscal 2025 Pre-Tax Profit of Up to AU$13.7 Million

MT Newswires Live

Dec 12, 2025

Vita Life Sciences (ASX:VLS) said it expects full-year pre-tax profit between AU$13.2 million to AU$13.7 million, compared to 2024 pre-tax profit of AU$12.6 million, according to a Friday Australian bourse filing.

The company expects fiscal year sales between AU$91 million to AU$92 million, compared to sales of AU$79.5 million a year earlier.

The company said that export sales into China are expected to be slightly below initial expectations due to trade partner transition timing and softer channel performance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2590520105"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2590520105\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2590520105?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-12 14:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590520105","market":"fut","top_or_hot":-1,"title":"Vita Life Sciences Expects Fiscal 2025 Pre-Tax Profit of Up to AU$13.7 Million","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/VLS.AU\">Vita Life Sciences</a> (ASX:VLS) said it expects full-year pre-tax profit between AU$13.2 million to AU$13.7 million, compared to 2024 pre-tax profit of AU$12.6 million, according to a Friday Australian bourse filing.</p><p>The company expects fiscal year sales between AU$91 million to AU$92 million, compared to sales of AU$79.5 million a year earlier.</p><p>The company said that export sales into China are expected to be slightly below initial expectations due to trade partner transition timing and softer channel performance.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vita Life Sciences Expects Fiscal 2025 Pre-Tax Profit of Up to AU$13.7 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVita Life Sciences Expects Fiscal 2025 Pre-Tax Profit of Up to AU$13.7 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-12 14:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/VLS.AU\">Vita Life Sciences</a> (ASX:VLS) said it expects full-year pre-tax profit between AU$13.2 million to AU$13.7 million, compared to 2024 pre-tax profit of AU$12.6 million, according to a Friday Australian bourse filing.</p><p>The company expects fiscal year sales between AU$91 million to AU$92 million, compared to sales of AU$79.5 million a year earlier.</p><p>The company said that export sales into China are expected to be slightly below initial expectations due to trade partner transition timing and softer channel performance.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2590520105","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590520105","pubTimestamp":1765519785,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Vita Life Sciences  said it expects full-year pre-tax profit between AU$13.2 million to AU$13.7 million, compared to 2024 pre-tax profit of AU$12.6 million, according to a Friday Australian bourse filing.The company expects fiscal year sales between AU$91 million to AU$92 million, compared to sales of AU$79.5 million a year earlier.The company said that export sales into China are expected to be slightly below initial expectations due to trade partner transition timing and softer channel performance.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","VLS.AU":"VITA LIFE SCIENCES LTD"},"translate_title":"Vita Life Sciences预计2025财年税前利润高达1370万澳元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VLS.AU":1},"content_text":"Vita Life Sciences (ASX:VLS) said it expects full-year pre-tax profit between AU$13.2 million to AU$13.7 million, compared to 2024 pre-tax profit of AU$12.6 million, according to a Friday Australian bourse filing.The company expects fiscal year sales between AU$91 million to AU$92 million, compared to sales of AU$79.5 million a year earlier.The company said that export sales into China are expected to be slightly below initial expectations due to trade partner transition timing and softer channel performance.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}